Skip to main content
Premium Trial:

Request an Annual Quote

Stephen Macevicz, Marc Funk, John Stuelpnagel, Steven Holtzman, James Serum, Robert Bishop


Stephen Macevicz has joined Aclara Biosciences as vice president of intellectual property, according to SEC filings. Macevicz, 53, was previously vice president of intellectual property at GeneProt, which he joined last year. Prior to that, he was VP of IP for Lynx Therapeutics, and before that was senior patent attorney and chief patent counsel at Applied Biosystems. He started at Aclara in March 2002.

GeneProt general counsel Marc Funk will continue to have oversight of legal affairs and IP, said a company representative.


Illumina said on May 10 that it had promoted John Stuelpnagel to senior vice president of operations. Stuelpnagel will oversee manufacturing, IP, scientific operations, engineering, R&D, and business development for the company. Stuelpnagel, 44, is one of the company’s founders and serves on Illumina’s board. He has served as acting president and chief executive officer, and was acting chief financial officer through April 2000.


Archemix said last week that it has appointed Steven Holtzman, chairman and CEO of Infinity Pharmaceuticals, to the company’s board of directors. Archemix, which is attempting to find therapeutic applications for aptamers, has also established a partnership with Ribozyme Pharmaceuticals to develop proteomics applications using aptamer technology. Prior to helping found Infinity, Holtzman served as chief business officer of Millennium Pharmaceuticals.


James Serum has joined Flagship Ventures as a venture partner, the Cambridge, Mass.-based company said last week. Serum, who most recently served as executive vice president, chief operating officer, and director of Viaken Systems, will join the life science team at Flagship. Prior to Viaken, Serum served in a number of scientific and management positions at Hewlett-Packard, including general manager for mass spectrometry, infrared, and protein chemical systems.


Caliper Technologies has brought on a new board member, Robert Bishop an appointment overshadowed by executive personnel changes last week. Bishop, 59, is board chair at AutoImmune, and was previously in senior management at Allergan. In addition, the company has proposed to shareholders that former CEO Daniel Kisner become board chair, and that new CEO Michael Knapp and new president James Knighton be named to the board.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.